静脉注射甲基强的松龙治疗甲状腺相关眼病性视神经病变的单中心疗效分析及相关因素。

A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.

机构信息

Department of Ophthalmology, Rangsit University, Rajavithi Hospital, 2 Phaya Thai Rd, Thung Phaya Thai, Ratchathewi, Bangkok, 10400, Thailand.

Faculty of Medicine Rajavithi Hospital, Rangsit University, 2 Phaya Thai Rd, Thung Phaya Thai, Ratchathewi, Bangkok, 10400, Thailand.

出版信息

BMC Ophthalmol. 2023 Jan 23;23(1):32. doi: 10.1186/s12886-023-02789-5.

Abstract

BACKGROUND

Dysthyroid optic neuropathy (DON) is a serious threatening vision loss in Graves' ophthalmopathy (GO). Although the European Group on Graves' Ophthalmopathy (EUGOGO) recommend intravenous methylprednisolone therapy for first line treatment, some characteristics predicting the response are still inconclusive.

AIM

To study the efficacy of intravenous pulse methylprednisolone (IVMP) in treating dysthyroid optic neuropathy (DON) and to identify factors predicting poor response to the treatment.

METHODS

All patients diagnosed with DON between January 2010 and December 2021 at Rajavithi Hospital, Thailand, receiving IVMP 1 g/ day for 3 consecutive days were analyzed. The efficacy at 1 week and 3, 6, 12-months in terms of improvement of best corrected visual acuity (BCVA) and proptosis were compiled.

RESULTS

Of the entire 57 DON cases that received IVMP, 50.9% gained at least 0.2 Logarithm of the Minimum Angle of Resolution (logMAR) at 1 week, and the improvement from initial to 1-week BCVA was 0.63 ± 0.63 logMAR (p < 0.001) and the decrease in proptosis was 1.8 ± 1.36 mm (p < 0.001). The remaining 23 orbits underwent orbital decompression and were excluded from the long-term efficacy analysis. In the last 12-months' follow-up time, there was an improvement of BCVA (0.53 ± 0.47 logMAR) and proptosis (0.59 ± 0.66 mm) (both p < 0.001). At last visit, there was an improvement of BCVA (0.2 logMAR) and proptosis (2 mm) in 76.5, and 5.9% respectively. Significant predictive factors of poor treatment response were age ≥ 55 years (odds ratio [OR]: 8.28, 95% confidence interval [CI]: 1.368-50.121, p = 0.021); longer onset duration before treatment (OR: 5.10, 95%CI: 1.061-24.501, p = 0.042); and proptosis at baseline (OR: 9.31, 95%CI: 1.872-46.280, p = 0.006). The strongest risk factor for predicting poor response to IVMP was poor initial visual acuity (OR: 10.26, 95%CI: 1.363-77.234, p = 0.024).

CONCLUSIONS

IVMP is effective for both short- and long-term treatment to improve visual acuity greater than proptosis. Older age, longer disease duration, poor initial visual acuity, and proptotic orbits were identified as risk factors for predicting poor response to IVMP treatment in Thai population. DON patients having those risk factors should be suspected, and treated early with IVMP to preserve their future vision.

摘要

背景

甲状腺相关眼病(GO)中的压迫性视神经病变(DON)可导致严重的视力丧失。尽管欧洲 Graves 眼病专家组(EUGOGO)推荐静脉内甲基强的松龙治疗作为一线治疗,但仍存在一些预测反应的特征尚不明确。

目的

研究静脉内脉冲甲基强的松龙(IVMP)治疗甲状腺相关眼病压迫性视神经病变(DON)的疗效,并确定预测治疗反应不良的因素。

方法

对 2010 年 1 月至 2021 年 12 月在泰国 Rajavithi 医院诊断为 DON 并接受 1 g/天,连续 3 天静脉注射甲基强的松龙的所有患者进行分析。根据最佳矫正视力(BCVA)和眼球突出度在 1 周、3、6、12 个月的改善情况来评估疗效。

结果

57 例 DON 患者中,50.9%在 1 周时至少获得 0.2 对数最小分辨角(logMAR)的改善,从初始到 1 周时 BCVA 的改善为 0.63±0.63 logMAR(p<0.001),眼球突出度的降低为 1.8±1.36 mm(p<0.001)。其余 23 例接受眼眶减压术,未纳入长期疗效分析。在最后 12 个月的随访期间,BCVA(0.53±0.47 logMAR)和眼球突出度(0.59±0.66 mm)均有改善(均 p<0.001)。最后一次就诊时,76.5%和 5.9%的患者 BCVA(0.2 logMAR)和眼球突出度(2 mm)分别有改善。治疗反应不良的显著预测因素为年龄≥55 岁(比值比 [OR]:8.28,95%置信区间 [CI]:1.368-50.121,p=0.021);治疗前发病时间较长(OR:5.10,95%CI:1.061-24.501,p=0.042);和基线时的眼球突出度(OR:9.31,95%CI:1.872-46.280,p=0.006)。预测 IVMP 治疗反应不良的最强危险因素是初始视力较差(OR:10.26,95%CI:1.363-77.234,p=0.024)。

结论

IVMP 对改善视力和眼球突出度均有短期和长期疗效。年龄较大、疾病持续时间较长、初始视力较差和眼球突出的眼窝被认为是泰国人群预测 IVMP 治疗反应不良的危险因素。具有这些危险因素的 DON 患者应怀疑存在该疾病,并早期接受 IVMP 治疗,以保护其未来视力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索